Millennia Portfolio Company, Collegium Pharmaceutical, Announces Positive Top-Line Data from Phase III Study of Oxycodone DETERx®

06 August, 2014

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced positive top-line results from its pivotal Phase 3 study of the company’s investigational analgesic Oxycodone DETERx® that studied the treatment of patients with moderate-to-severe chronic low back pain.